Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) reported Q1 2026 revenue of $19.7M (+13% Y/Y), with Interventional Glaucoma at $18.3M and Interventional Dry Eye at $1.4M (up 244% Y/Y). Gross margin was 86%. Q1 net loss was $13.0M (−$0.24 per share). Cash totaled $85.0M and long-term debt was $40.0M as of March 31, 2026. The company raised 2026 revenue guidance to $83.0M–$89.0M and reaffirmed adjusted operating expense guidance of $93.0M–$96.0M. A Delaware court awarded $55.4M plus a 10% ongoing royalty in a patent judgment, subject to appeal.
Sight Sciences (NASDAQ: SGHT) will present at two investor conferences in May 2026: the BofA Securities 2026 Health Care Conference in Las Vegas on May 13, 2026 at 3:15 pm PT / 6:15 pm ET, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026 at 9:00 am PT / 12:00 pm ET.
According to Sight Sciences, interested parties can access live and archived webcasts via the company’s Investors website.
Sight Sciences (NASDAQ: SGHT) published its third annual Sustainability Report on April 22, 2026, covering 2023–2025 environmental, social, and governance activities. Key figures include donations to 24 programs in 24 countries, a reported >20% reduction in Scope 1–3 emissions in 2025, and a workforce of 187 with 56% women.
The report details energy and waste initiatives, emissions reporting, community programs, pay equity, employee development, and governance oversight by the Nominating and Corporate Governance committee.
Sight Sciences (Nasdaq: SGHT) said it will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will review the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the company Investors page, with replay accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) announced clinical data presentations for its OMNI Surgical System and TearCare System at the 2026 ASCRS Annual Meeting in Washington, DC on April 11. According to the company, OMNI data show reduced long-term diurnal IOP fluctuations regardless of lens status, while TearCare data report early and sustained superiority over Restasis for tear film stability.
Presentations include TearCare oral and poster sessions on April 11 and an OMNI poster on longer-term diurnal IOP following canaloplasty and trabeculotomy; lead and presenting authors are named.
Sight Sciences (Nasdaq: SGHT) will present at the 25th Annual Needham Healthcare Conference on Monday, April 13, 2026 at 11:15 am PT / 2:15 pm ET. Management will deliver a fireside chat available via live and archived webcast.
Investors can access the webcast on the company’s Investors website for a live stream and later replay.
Sight Sciences (Nasdaq: SGHT) announced a U.S. District Court order (entered March 27, 2026) that preserved a jury verdict finding Alcon willfully infringed three Sight Sciences patents and awarded monetary damages in excess of $34 million.
The order also provides an ongoing royalty of 10% of Hydrus revenue through November 10, 2028. A final judgment will follow after supplemental damages and pre-judgment interest are calculated; the judgment is subject to appeal and USPTO reexamination. The company expects a $5.4 million success fee to operating expenses payable to its counsel.
Sight Sciences (Nasdaq: SGHT) reported Q4 2025 revenue of $20.4M (+7% YoY) and full-year 2025 revenue of $77.4M (‑3% YoY). Gross margin was 87% in Q4 and 86% for FY2025. Adjusted operating expenses fell 13% year-over-year. Cash totaled $92.0M at year-end. The company provided 2026 guidance of $82M–$88M revenue and adjusted operating expenses of $93M–$96M.
Management cited commercial traction in glaucoma and dry eye and a pathway toward cashflow breakeven.
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live webcast and archived replay will be available on the company's Investors page. The replay will be accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) provided preliminary, unaudited Q4 and full-year 2025 financial highlights for the period ended December 31, 2025. Q4 2025 revenue is expected to be $20.3M–$20.4M (≈+7% at midpoint). Full-year 2025 revenue is expected to be $77.3M–$77.4M (≈-3% at midpoint). Q4 Dry Eye revenue is ~$0.7M (+~130% YoY); full-year Dry Eye revenue is ~$1.6M vs $4.0M in 2024. Cash and cash equivalents were approximately $92M at Dec 31, 2025; cash used in 2025 totaled ~$28M. Results are preliminary and subject to audit with final results expected in March 2026.